Buspirone in the Treatment of Anxiety Disorders

Anxiety Disorders

Volumn , Issue , 2007, Pages 381-397

  Rickels, K ^a   Khalid Khan, S ^a   Rynn, M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Anxiety disorders; Buspirone; Premenstrual syndrome; Sedation; Toxicity

Indexed keywords

EID: 84951946331     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470986844.ch20     Document Type: Chapter

References (137)

1. American Psychiatric Association (1987) Diagnostic Statistical Manual of Mental Disorders, 3rd edn revised. American Psychiatric Association, Washington, D.C.
2. American Psychiatric Association (1994) Diagnostic Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, D.C.
3. Anderson, I.M. & Cowen, P.J. (1992) Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology 106, 428-30.
4. Argyropoulou, P., Patakas, D., Koukou, A. et al. (1993) Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 60, 216-20.
5. Barbhaiya, R.H., Shukla, J.A., Pfeffer, M. et al. (1994) Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 46, 41-7.
6. Bohm, C., Placchi, M., Stallone, F. et al. (1990a) A doubleblind comparison of buspirone, clobazepam, and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 10, 385-425.
7. Bohm, C., Robinson, D.S., Gammans, R.E. et al. (1990b) Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol 10 (Suppl.), 47-51.
8. Boulenger, J.-P., Gram, L.F., Jolicoeur, F.B. et al. (1993) Repeated administration of buspirone: absence of pharmacodynamic or pharmacokinetic interaction with triazolam. Hum Psychopharmacol 8, 117-24.
9. Boulenger, J.P., Squillace, K., Simon, P. et al. (1989) Buspirone and diazepam: comparison of subjective, psychomotor and biological effects. Neuropsychobiology 22, 83-9.
10. Brown, T.A. & Barlow, D. (1992) Comorbidity among anxiety disorders: implications for treatment and DSM-IV. J Consult Clin Psychol 60, 835-44.
11. Brown, C.S., Ling, F.W., Farmer, R.G. et al. (1990) Buspirone in the treatment of premenstrual syndrome. Drug Ther Bull 8 (Suppl.), 112-16.
12. Buch, A.B., Van Harken, D.R., Seidehamel, R.J. et al. (1999) A study of pharmacokinetic interaction between buspirone and alprazolam at steady state. J Clin Pharmacol 33, 1104-9.
13. Buitelaar, J.K. (1995) Psychopharmacological approaches to childhood psychotic disorders. In: Advances in the Neurobiology of Schizophrenia. (J.A. Den Boer, H.G.M. Westenberg & H.M. Van Praag (eds), pp. 429-57). John Wiley & Sons, New York.
14. Buitelaar, J.K., Rutger, J., van der Gaag & van der Hoeven, J. (1998) Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 59, 56-9.
15. Caccia, S., Vigano, G.L., Mingardi, G. et al. (1988) Clinical pharmacokinetics of oral buspirone in patients with impaired renal function. Clin Pharmacokinet 14, 171-7.
16. Campbell, M., Adams, P., Perry, R. et al. (1988) Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull 24, 251-5.
17. Campbell, M., Anderson, L.T., Meier, M. et al. (1978) A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17, 640-55.
18. Cantillon, M., Brunswick, R., Molina, D. et al. (1996) Buspirone versus haloperidol. A double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4, 236-67.
19. Charney, D.S. & Heninger, G.R. (1985) Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry 42, 458-67.
20. Chiaie, R., Pancheri, P., Cassacchia, M. et al. (1995) Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 15, 12-19.
21. Cinciripini, P.M., Lapitsky, L., Seay, S. et al. (1995) A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high-and low-anxiety smokers. J Clin Psychopharmacol 15, 182-91.
22. Cohen, D.J., Paul, R. & Volkmar, F.R. (1986) Issues in the classification of pervasive and other developmental disorders: toward DSM-IV. J Am Acad Child Psychiatry 25, 213-20.
23. Cohn, J.B., Bowden, C.L., Fisher, J.G. & Rodos, J. (1986a) Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 80, 10-16.
24. Cohn, J.B. & Rickels, K. (1989) A pooled, double-blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Curr Med Res Opin 11, 304-20.
25. Craven, J. & Sutherland, A. (1991) Buspirone for anxiety disorders in patients with severe lung disease [letter]. Lancet 338, 249.
26. Cutler, N., Sramek, J., Hesselink, J.M.K. et al. (1993) A doubleblind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 13, 429-37.
27. Dalhoff, K., Poulsen, H.E., Garred, P. et al. (1987) Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 24, 547-50.
28. Davidson, J.R., Dupont, R.L., Hedges, D. & Haskins, J.T. (1999) Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60, 528-35.
29. De Montigny, C. & Blier, P. (1992) Potentiation of 5-HT neurotransmission by short-term lithium: in vivo electrophysiological studies. Clin Neuropsychopharmacol 15, 610A-11A.
30. De Roeck, J., Dluydts, R., Schotte, C. et al. (1989) Explorative single-blind study on the sedative and hypnotic effects of buspirone in anxiety patients. Acta Psychiatr Scand 79, 129-35.
31. Demartinis, N., Rynn, M., Rickels, K. & Mandos, L. (2000) Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry 61, 91-4.
32. Dement, W.C., Seidel, W.F., Cohen, S.A. et al. (1991) Effects of alprazolam, buspirone and diazepam on daytime sedation and performance. Drug Invest 3, 148-56.
33. Dimitriou, E.C. & Dimitriou, C.E. (1998) Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 18, 465-9.
34. Dimitriou, E.C., Parashos, A.J. & Giouzepas, J.S. (1992) Buspirone versus alprazolam. A double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms. Drug Invest 4, 316-21.
35. Duffy, J.D. & Molloy, P.F. (1994) Efficacy of buspirone in the treatment of post-traumatic stress disorder: an open trial. Ann Clin Psychiatry 6, 33-7.
36. Eison, A.S. & Temple D.L., Jr (1986) Buspirone. Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 80, 1-9.
37. Eison, A.S. (1990) Azapirones. mechanism of action in anxiety and depression. Drug Ther 20 (Suppl.), 3-8.
38. Enkelmann, R. (1991) Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 105, 428-32.
39. Erwin, C.W., Linnoila, M., Hartwell, J. et al. (1986) Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol 6, 199-209.
40. Fabre, L.F. (1990) Buspirone in the management of major depression: a placebo-controlled comparison. J Clin Psychiatry 51 (Suppl.), 55-61.
41. Feighner, J.P. & Cohen, J.B. (1989) Analysis of individual symptoms in generalized anxiety-a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 21, 124-30.
42. Feighner, J.P., Merideth, C.H. & Hendrickson, G.A. (1982) A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 43, 103-7.
43. Fulton, B. & Brogden, R.N. (1997) Buspirone. An updated review of its clinical pharmacology and therapeutic applications. CNS Drugs 7, 68-88.
44. Gammans, R.E., Kerns, E.H. & Bullen, W.W. (1985) Capillary gas chromatographic-mass spectrometric determination of buspirone in plasma. J Chromatogr 345, 285-97.
45. Gammans, R.E., Mayol, R.F. & Labudde, J.A. (1986) Metabolism and disposition of buspirone. Am J Med 80 (Suppl. 3B), 41-51.
46. Gammans, R.E., Pfeffer, M., Westrick, M.L. et al. (1987) Lack of interaction between cimetidine and buspirone. Pharmacotherapy 7, 72-9.
47. Gammans, R.E., Westrick, M.L., Shea, J.P. et al. (1989) Pharmacokinetics of buspirone in elderly subjects. J Clin Pharmacol 29, 72-8.
48. Goa, K.L., Ward, A. & Buspirone, A. (1986) Preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32, 114-29.
49. Goff, D.C., Midha, K.K., Brotman, A.W. et al. (1991) An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11, 193-7.
50. Goldberg, H.L. & Finnerty, R.J. (1979) The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 136, 1184-7.
51. Goldberg, H.L. & Finnerty, R. (1982) Comparison of bus-pirone in two separate studies. J Clin Psychiatry 43, 87-91.
52. Goldberg, R.J. (1994) The use of buspirone in geriatric patients. J Clin Psychiatry 12, 31-2.
53. Gonul, A.S., Oguz, A., Yabanoglu, I., Aslan, S.S. & Turan, T. (1999) Buspirone and pindolol in augmentation therapy of treatment-resistant depression. Eur Neuropsychopharmacol 9 (Suppl. 5), S215.
54. Greenblatt, D.J., Harmatz, J.S., Gouthro, T.A. et al. (1994) Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: kinetic-dynamic studies. Clin Pharmacol Ther 56, 100-11.
55. Gregory, C.A., Anderson, I.M. & Cowen, P.J. (1990) Metergoline abolishes the prolactin response to buspirone. Psychopharmacology Berl 100, 283-4.
56. Gualtieri, C.T. (1991) Buspirone for the behavior problems of patients with organic brain disorders [letter]. J Clin Psychopharmacol 11, 280-1.
57. Hamilton, M.A. (1959) The assessment of anxiety states by rating. Br J Med Psychol 32, 50-5.
58. Hart, R.P., Colenda, C. & Hamer, R.M. (1991) Effects of buspirone and alprazolam on the cognitive performance of normal elderly subjects. Am J Psychiatry 148, 73-7.
59. Hilleman, D.E., Mohiuddin, S.M., Del Core, M.G. et al. (1992) Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 152, 350-2.
60. Jajoo, H.K., Mayol, R.F., LaBudde, J.A. et al. (1989) Metabolism of the antianxiety drug buspirone in human subjects. Drug Metab Dispos 17, 634-40.
61. Jann, M.W., Huang, H.F., Chang, T.P. et al. (1996) Lack of pharmacokinetic interactions between buspirone and haloperidol in schizophrenic patients [abstract no. P-2-1]. Eur Neuropsychopharmacol 6 (Suppl. 3), 37.
62. Jenike, M.A., Baer, L. & Buttolph, L. (1991) Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. J Clin Psychiatry 52, 13-14.
63. Joshi, P.T., Capozzoli, J.A. & Coyle, J.T. (1988) Low-dose neuroleptic therapy for children with childhood-onset per-vasive developmental disorder. Am J Psychiatry 145, 335-8.
64. Kendler, K.S., Neale, M.C., Kessler, R.C. et al. (1992) Major depression and generalized anxiety disorder: same genes, (partly) different environments? Arch Gen Psychiatry 49, 716-22.
65. Kiev, A. & Domantay, A.G. (1988) A study of buspirone coprescribed with bronchodilators in 82 anxious ambulatory patients. J Asthma 25, 281-4.
66. Kiev, A. & Domantay, A.G. (1989) A study of buspirone coprescribed with nonsteroidal antinflammatory drugs in 150 anxious ambulatory patients. Curr Ther Res 46, 1086-90.
67. Kranzler, H.R., Burleson, J.A. & Del, B.F.K. et al. (1994) Buspirone treatment of anxious alcoholics: a placebo-controlled trial. Arch Gen Psychiatry 51, 702-31.
68. Kushner, M.G., Sher, K.J. & Beitman B.D. (1990) The rela-tion between alcohol problems and the anxiety disorders. Am J Psychiatry 147, 685-95.
69. Kutcher, S.P., Reiter, S., Gardener, D.M. et al. (1992) The pharmacotherapy of anxiety disorders in children and adolescents. Psychiatr Clin North Am 15, 41-66.
70. Laakman, G., Schule, C., Lorkowski, G., Baghai, T., Kuhn, K. & Ehrentraut, S. (1998) Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 136, 357-66.
71. van Laar, M.W., Volkerts, E.R. & van Willigenburg, A.P. (1992) Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. J Clin Psychopharmacol 12, 86-95.
72. Lader, M. & Scotto, J.C. (1998) A multicenter double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology 139, 402-6.
73. Lamberg, T.S., Kivisto, K.T. & Neuvonen, P.J. (1998) Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone. Clin Pharmacol Ther 63, 640-5.
74. Landen, M., Bjorling, G., Agren, H. & Fahlen, T. (1998) A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 59, 664-8.
75. Langlois, R.P. & Paquette, D. (1994) Sustained bradycardia during fluvoxamine and buspirone intoxication. Can J Psychiatry 39, 126-7.
76. Lilja, J.J., Kivisto, K.T., Backman, J.T., Lamberg, T.S. & Neuvonen, P.J. (1998) Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther 64, 655-60.
77. Littman, A.B., Fava, M., McKool, K. et al. (1993) Buspirone therapy for Type A behavior, hostility, and perceived stress in cardiac patients. Psychother Psychosom 59, 107-10.
78. Lucki, I., Rickels, K., Giesecke, A. & Geller, A. (1987) Differential effects of the anxiolytic drugs, diazepam and buspirone on memory function. Br J Clin Pharmacol 23, 207-11.
79. Malcolm, R., Anton, R.F., Randall, C.L. et al. (1992) A placebo-controlled trial of buspirone in anxious inpatient alcoholics. Alcohol Clin Exp Res 16, 1007-13.
80. Manfredi, R.L., Kales, A., Vgontzas A. et al. (1991) Buspirone: sedative or stimulant effect? Am J Psychiatry 148, 1213-17.
81. Mattila, M.J., Aranko, K. & Seppala, T. (1982) Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry 43, 56-60.
82. Mayol, R.F., Gammans, R.E., Mackenthun, A.V. et al. (1983) The effect of food on the bioavailability of buspirone HCl [abstract]. Clin Res 31, 631a.
83. Moskowitz, H. & Smiley, A. (1982) Effects of chronically administered buspirone and diazepam on driving-related skills performance. J Clin Psychiatry 43, 45-55.
84. Moss, L.E. & Neppe, V.M. & Drevets, W.C. (1993) Buspirone in the treatment of tardive dyskinesia. J Clin Psychopharmacol 13, 204-9.
85. Munjack, D.J., Bruns, J., Baltazar, P.L. et al. (1991) A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord 5, 87-98.
86. Murphy, S.M., Owen, R. & Tyrer, P. (1989) Comparative assessment of efficacy and withdrawal symptoms after 6 and 12 weeks' treatment with diazepam or buspirone. Br J Psychiatry 154, 529-34.
87. Napoliello, M.J. (1986) A study of buspirone coprescribed with antidepressants in 184 anxious ambulatory patients. Curr Ther Res 40, 917-23.
88. Neppe, V.M. (1989) High-dose buspirone in a case of tardive dyskinesia [letter]. Lancet 2, 8677.
89. Newton, R.E., Marunycz, J.D., Alderdice, M.T. et al. (1986) Review of the side-effect profile of buspirone. Am J Med 80 (Suppl. 3B), 17-21.
90. Norden, M.J. (1994) Buspirone treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Depression 2, 109-12.
91. Olivier, B., van Wijngaarden, I. & Soudijn, W. (2000) 5-HT3 receptor antagonists and anxiety; a preclinical and clinical review. Eur Neuropsychopharmacol 10, 77-95.
92. Othmer, E. & Othmer, S.C. (1987) Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder. J Clin Psychiatry 48, 201-3.
93. Pascual, J. & Berciano, J. (1991) An open trial of buspirone in migraine prophylaxis: preliminary report. Clin Neuropharmacol 14, 245-50.
94. Pato, M.T., Pigott, T.A., Hill, J.L. et al. (1991) Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 148, 127-9.
95. Pecknold, J.C. (1994) Serotonin 5-HT1A agonists. a comparative review. CNS Drugs 2, 234-51.
96. Pecknold, J.C., Matas, M., Howarth, B.G. et al. (1989) Evaluation of buspirone as an antianxiety agent: buspirone and diazepam versus placebo. Am J Psychiatryry 34, 766-71.
97. Phillips, K.A. (1996) An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull 32(1), 175-80.
98. Pohl, R., Balon, R., Yeragani, V.K. et al. (1989) Serotonergic anxiolytics in the treatment of panic disorder: a controlled study with buspirone. Psychopathology 22 (Suppl. 1), 60-7.
99. Pollicino, A.M., Spina, E., Campo, G.M. et al. (1992) Pharmacokinetics interactions between tricyclic antidepressants and other psychotropic drugs in depressed patients. Pharmacol Res 25 (Suppl. 2), 210-11.
100. Rakel, R.E. (1990) Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 83, 194-8.
101. Rapaport, D.M., Greenberg, H.E. & Goldring, R.M. (1991) Differing effects of the anxiolytic agents buspirone and diazepam on control of breathing. Clin Pharmacol Ther 49 394-401.
102. Ratey, J.J., Leveroni, C.L., Miller, A.C. et al. (1992) Lowdose buspirone to treat agitation and maladaptive behavior in brain-injured patients: two case reports [letter]. J Clin Psychopharmacol 12, 362-4.
103. Realmuto, G.M., August, G.J. & Garfinkel, B.D. (1989) Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 9, 122-5.
104. Rickels, K. & Schweizer, E. (1990) The clinical course and long-term management of generalized anxiety disoder: J Clin Psychopharmacol 10, 101S-10S.
105. Rickels, K., Amsterdam, J.D., Clary, C. et al. (1991) Buspirone in major depression: a controlled study. J Clin Psychiatry 52, 34-8.
106. Rickels, K., DeMartinis, N., Garcia-Espana, F., Greenblat, D., Mandos, L. & Rynn, M. (2000) Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry 157, 1973-9.
107. Rickels, K., Downing, R., Scheweizer, E. & Hassman, H. (1993) Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50, 884-95.
108. Rickels, K., Freeman, E. & Sondheimer, S. (1989) Bus-pirone in treatment of premenstrual syndrome. Lancet 1, 777.
109. Rickels, K., Schweizer, E., Csanalosi, I. et al. (1988) Longterm treatment of anxiety and risk of withdrawal: pro-spective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45, 444-50.
110. Rickels, K., Schweizer, E., DeMaritinis, N., Mandos, L. & Mercer, C. (1997) Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 17, 272-7.
111. Rickels, K., Wiseman, K., Norstad, N. et al. (1982) Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43, 81-6.
112. Ritchie, L.D. & Cox, J. (1993) A multicenter study of bus-pirone in the treatment of anxiety disorders in the elderly. Br J Clin Res 4, 131-9.
113. Robinson, D., Napoliello, M.J. & Schenk, J. (1988) The safety and usefulness of buspirone as an anxiolytic drug in the elderly versus young patients. Clin Ther 10, 740-6.
114. Sacchetti, E., Zerbini, O., Banfi, F. et al. (1994) Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: findings from a controlled, multicenter, double-blind study. Hum Psychopharmacol 9, 409-22.
115. Schaffler, K. & Klausnitzer, W. (1989) Placebo-controlled study on acute and subchronic effects of buspirone versus bromazepam utilizing psychomotor and cognitive assessments in healthy volunteers. Pharmacopsychiatry 22, 26-33.
116. Scheibe, G. (1996) Four-year follow-up in 40 outpatients with anxiety disorders: buspirone versus lorazepam. Eur J Pscyhiat 10, 25-34.
117. Schweizer, E., Amsterdam, J., Rickels, K. et al. (1986) Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 22, 183-5.
118. Schweizer, E. & Rickels, K. (1986) Failure of buspirone to manage benzodiazepine withdrawal. Am J Psychiatry 143, 1590-2.
119. Schweizer, E. & Rickels, R. (1994) New and emerging clinical uses for buspirone. J Clin Psychiatry Monograph 12, 1.
120. Schweizer, E. & Rickels, K. (1995) Buspirone and related 5-HT compounds as anxiolytics. In: Hypnotics and Anxiolytics (D.J. Nutt & W.B. Mendelson (eds), pp. 447-66). Bailliere Tindall, London.
121. Schweizer, E., Rickels, K. & Lucki, I. (1986) Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 314, 719-20.
122. Schweizer, E., Rickels, K., Hassman, H. & Garcia-Espana, F. (1998) Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 59, 175-83.
123. Sellers, E.M., Schneiderman, J.F., Romacch, M.K. et al. (1992) Comparative drug effects and abuse liability of lorazepam, buspirone, and secobarbital in nondependent subjects. J Clin Psychopharmacol 12, 79-85.
124. Sheehan, D.V., Raj, A.B., Harnett-Sheehan, K. et al. (1993) The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebocontrolled study. Acta Psychiatr Scand 88, 1-11.
125. Simeon, J.G., Knott, V.J., Dubois, C. et al. (1994) Buspirone therapy of mixed anxiety disorders in childhood and adolescence: a pilot study. J Child Adolesc Psychophamacol 4, 159-70.
126. Sramek, J.J., Tansman, M., Suri, A. et al. (1996) Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry 57, 287-91.
127. Stahl, S.M., Kaiser, L., Roeschen, J., Kepper-Hesselink, J.M. & Orazem, J. (1998) Effectiveness of ipsapirone, a 5-HT1A partial agonist, in major depressive disorder. Support for the role of 5-HT1A receptors in the mechanism of action of serotonergic antidepressants. Int J Neuropsychopharmacol 1, 11-18.
128. Strand, M., Hetta, J., Rosen, A. et al. (1990) A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 51 (Suppl.), 40-5.
129. Tollefson, G.D., Godes, M., Montague-Clouse, J. et al. (1989) Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. J Clin Psychopharmacol 9, 132-6.
130. Tollefson, G.D., Montague-Clouse, J. & Tollefson, S.L. (1992) Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone). J Clin Psychopharmacol 12, 19-26.
131. Troisi, I.I.J.R., Critchfield, T.S. & Griffiths, R.R. (1993) Buspirone and lorazepam abuse liability in humans. Beha-vioral effects, subjective effects and choice. Behav Pharmacol 4, 217-30.
132. Tunnicliff, G. (1991) Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 69, 149-56.
133. Tyrer, P., Seivewright, N., Ferguson, B. et al. (1992) The general neurotic syndrome: a coaxial diagnosis of anxiety, depression and personality disorder. Acta Psychiatr Scand 85, 201-6.
134. Udelman, H.D. & Udelman, D.L. (1990) Concurrent use of buspirone in anxious patients during withdrawal from alprazolam therapy. J Clin Psychiatry 51(9) (Suppl.), 46-50.
135. Vliet, I.M., den Boer, J.A.D., Westenberg, H.G.M. & Ho Pian, K.L. (1997) Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58, 164-8.
136. West, R., Hajek, P. & McNeill, A. (1991) Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers' clinic. Psychopharmacology 104, 91-6.
137. Wheatley, D. (1982) Buspirone. Multicenter efficacy study. J Clin Psychiatry 43, 92-4.